Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.33 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.33 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.32 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.32 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29377696 | 1.00 | ADRB3 (0.35) | ADRB3CA12CA2CYP2A6MMP2 | |
| Hydrochloric Acid SCHEMBL3083871 | 1.00 | ADRB3 (0.35) | ADRB3CA12CA2CYP2A6MMP2 | |
| SCHEMBL15562859 | 0.99 | ADRB3 (0.35) | ADRB3CA12CA2CYP2A6MMP2 | |
| SCHEMBL9308678 | 0.99 | ADRB3 (0.35) | ADRB3CA12CA2CYP2A6MMP2 | |
| SCHEMBL9309505 | 0.91 | SIGMAR1 (0.35) | ADRB3CA12CA2CYP2A6MMP2 | |
| Hydrochloric Acid SCHEMBL28265 | 0.88 | SMN1; SMN2 (0.34) | ADRB3CA12CA2CYP2A6MMP2 | |
| Hydrochloric Acid SCHEMBL3088634 | 0.88 | SMN1; SMN2 (0.34) | ADRB3CA12CA2CYP2A6MMP2 | |
| SCHEMBL9308713 | 0.86 | KDM4E (0.34) | ADRB3CA12CA2CYP2A6MMP2 | |
| SCHEMBL9309462 | 0.86 | KDM4E (0.34) | ADRB3CA12CA2CYP2A6MMP2 | |
| SCHEMBL29608 | 0.86 | KDM4E (0.34) | ADRB3CA12CA2CYP2A6MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262268-A1 | ORAL MODIFIED RELEASE FORMULATIONS | RUBICON RES PRIVATE LIMITED (IN) | 2019-08-29 | — | — | US | claimed |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | GLOBAL CANCER TECHNOLOGY INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12049462-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | NEUROPORE THERAPIES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11492348-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | NEUROPORE THERAPIES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-110167937-B | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB生物制药私人有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11091474-B2 | Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-08-17 | — | — | US | disclosed |
| US-20210163462-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-01-12 | — | — | US | disclosed |
| US-20200308163-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-5719150-A | ALZHEIMER'S DISEASE | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5658904-A | COGNITION ACTIVATORS; BRAIN DISORDERS; ALZHEIMER*S DISEASE | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5612381-A | 1,2-ethanediol derivative and salt thereof process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-03-18 | — | — | US | disclosed |
| US-5472984-A | 1,2-ethanediol derivative and salt thereof and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1995-12-05 | — | — | US | disclosed |
| EP-0383281-B1 | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO LTD (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0589484-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-30 | — | — | EP | disclosed |
| EP-0587194-A1 | 2-(Heterocycloalkoxy)-1-(subst.-phenyl)-ethanol derivatives as cerebral function improving agents | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0587193-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-5280032-A | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-01-18 | — | — | US | disclosed |
| EP-0383281-A1 | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | ADRB3 2970/4885CA2 4271/4885MMP13 2944/4885 |
| US-11492348-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | ATG7, ULK1, BECN1 | ADRB3 1467/4885CA2 4452/4885MMP13 2792/4885 |
| US-20210163462-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | ATG7, ULK1, BECN1 | ADRB3 1467/4885CA2 4452/4885MMP13 2792/4885 |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | PIK3R4, PIK3R1, ATG7 | ADRB3 968/4885CA2 3221/4885MMP13 4095/4885 |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | PARK7, HTT, SNCA | ADRB3 2490/4885CA2 4254/4885MMP13 2517/4885 |
| US-20200308163-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | ADRB3 2970/4885CA2 4271/4885MMP13 2944/4885 |
| US-12049462-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | ATG7, ULK1, BECN1 | ADRB3 1402/4885CA2 4458/4885MMP13 2833/4885 |
| US-11091474-B2 | Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation | PARK7, HTT, SNCA | ADRB3 2066/4885CA2 4336/4885MMP13 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.